Rational Advisors’s Myriad Genetics MYGN Stock Holding History

Rational Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-11,000	Closed	-$337K	–	295
2016 Q2	$337K	Hold	11,000	–	–	0.23%	102
2016 Q1	$412K	Buy	+11,000	New	+$414K	0.27%	109
2015 Q3	$3.95M	Sell	105,500 -105,500	-50%	-$3.74M	1.6%	3
2015 Q2	$7.17M	Sell	211,000 -42,200	-17%	-$1.43M	2.31%	2
2015 Q1	$8.96M	Buy	253,200 +3,200	+1%	+$115K	2.17%	3
2014 Q4	$8.52M	Buy	+250,000	New	+$8.87M	1.69%	5
2013 Q4	$3.82M	Hold	182,000	–	–	0.33%	99
2013 Q3	$4.28M	Buy	182,000 +40,000	+28%	+$1.14M	0.33%	83
2013 Q2	$3.82M	Buy	+142,000	New	+$4.12M	0.32%	101

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Rational Advisors's MYGN Position: Q3 2016 in Review

Rational Advisors sold out of Myriad Genetics (MYGN) in Q3 2016, closing a stake of 11,000 shares — an estimated $337K sold.

Rational Advisors first reported a position in MYGN in Q2 2013 and held it in 9 quarters. The position peaked at $8.96M in Q1 2015. 223 funds tracked by Wall St. Rank hold MYGN as of Q3 2016.

Rational Advisors reported no remaining Myriad Genetics position as of Q3 2016 after selling out during the quarter.
Rational Advisors sold 11,000 Myriad Genetics shares in Q3 2016, an estimated $337K.
Rational Advisors first reported a position in Myriad Genetics in Q2 2013 and held it in 9 quarters.
Rational Advisors's Myriad Genetics position peaked at $8.96M in Q1 2015.
223 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2016.

Based on Rational Advisors's 13F filing for Q3 2016, filed 10 Nov 2016.